Sign up to save your podcasts
Or
Share Experts Talk CLL #9 : Relapsing on Novel Agents: What's Next?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #9 : Relapsing on Novel Agents: What's Next?
A discussion between Dr. Peter Anglin and Dr. John F. Seymour (October 2022)
Dr. Anglin and Dr. Seymour discuss the management of CLL patients progressing on novel continuous therapies (BTK inhibitors) as well as after novel time-limited therapies (venetoclax-based regimens). They emphasize the importance of understanding the underlying reason(s) for progression/treatment failure. Dr. Seymour describes his practice of switching from BTK inhibitors to venetoclax-based therapies and vice versa and factors that impact his approaches and choice of subsequent therapy.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
John F. Seymour, AM, FAHMS, MB, BS, PhD, FRACP, Professor of Medicine, University of Melbourne, Director, Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. John F. Seymour (October 2022)
Dr. Anglin and Dr. Seymour discuss the management of CLL patients progressing on novel continuous therapies (BTK inhibitors) as well as after novel time-limited therapies (venetoclax-based regimens). They emphasize the importance of understanding the underlying reason(s) for progression/treatment failure. Dr. Seymour describes his practice of switching from BTK inhibitors to venetoclax-based therapies and vice versa and factors that impact his approaches and choice of subsequent therapy.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
John F. Seymour, AM, FAHMS, MB, BS, PhD, FRACP, Professor of Medicine, University of Melbourne, Director, Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.